

CITATION REPORT

List of articles citing

Rapamycin: something old, something new, sometimes borrowed and now renewed

DOI: 10.1038/sj.clpt.6100317

Clinical Pharmacology and Therapeutics, 2007, 82, 381-8.

Source: <https://exaly.com/paper-pdf/42814520/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
205	Laboratory Medicine in Transplantation. 342-372		
204	De mTOR-remmers: veelbelovend, maar veel van hetzelfde. 2008 , 46, 18-18		
203	Insights into the PI3-K-PKB-mTOR signalling pathway from small molecules. 2008 , 1, 49-62		20
202	Prophylaxis of acute GVHD: manipulate the graft or the environment?. 2008 , 21, 165-76		29
201	Rapamycin suppresses TLR4-triggered IL-6 and PGE(2) production of colon cancer cells by inhibiting TLR4 expression and NF-kappaB activation. 2008 , 45, 2929-36		42
200	Rapamycin reverses TLR4 signaling-triggered tumor apoptosis resistance by disrupting Akt-mediated Bcl-xL upregulation. 2008 , 8, 1854-8		12
199	Recommended changes to oncology clinical trial design: revolution or evolution?. 2008 , 44, 8-11		31
198	The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. 2008 , 67 Suppl 3, iii70-4		178
197	ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. 2008 , 7, 3265-74		64
196	Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangiomyomatosis-derived cell proliferation. 2008 , 73, 778-88		17
195	Generation and characterization of monoclonal antibodies to mTOR kinase. 2008 , 27, 395-9		2
194	Current Opinion in Organ Transplantation. Current world literature. 2008 , 13, 551-62		
193	Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. 2008 , 15, 88-94		26
192	Autophagy: healthy eating and self-digestion for gastroenterologists. 2008 , 46, 496-506		8
191	Eficácia, tolerabilidade e segurança do uso do sirolimo após o transplante renal. 2009 , 31, 258-268		1
190	Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. 2009 , 182, 2063-73		171
189	mTOR-blocking agents in advanced renal cancer: an emerging therapeutic option. 2009 , 18, 175-87		9

188	PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. 2009 , 8, 403-13	71
187	Novel and evolving therapies in the treatment of malignant pheochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). 2009 , 41, 697-702	82
186	Rapamycin prevents transforming growth factor-alpha-induced pulmonary fibrosis. 2009 , 41, 562-72	76
185	Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model. 2009 , 15, 6096-105	97
184	Protective role of autophagy in palmitate-induced INS-1 beta-cell death. 2009 , 150, 126-34	153
183	Ready for a comeback of natural products in oncology. 2009 , 77, 1447-57	86
182	Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation. 2009 , 78, 1242-51	124
181	Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. 2009 , 30, 517-23	3
180	Apoptosis and autophagy: Targeting autophagy signalling in cancer cells - is or treats s . 2009 , 276, 6084-96	100
179	Regulation of the aging process by autophagy. 2009 , 15, 217-24	209
178	Rationale and design of the Patient Related Outcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. 2009 , 158, 902-909.e5	38
177	mTOR Mediated Anti-Cancer Drug Discovery. 2009 , 6, 47-55	133
176	Novel targets in esophageal and gastric cancer: beyond antiangiogenesis. 2009 , 18, 1351-64	18
175	Dendritic Cells. 2009 ,	2
174	Use of rapamycin in the induction of tolerogenic dendritic cells. 2009 , 215-32	55
173	Inhibition of autophagy causes tau proteolysis by activating calpain in rat brain. 2009 , 16, 39-47	29
172	Activation of the PI3K-Akt-mTOR signaling pathway promotes necrotic cell death via suppression of autophagy. 2009 , 5, 824-34	175
171	Emerging concepts in the pathogenesis of lung fibrosis. 2009 , 175, 3-16	177

170	Natural compounds for cancer treatment and prevention. 2009 , 59, 365-78	464
169	The Biological Role of mTOR in the Pathogenesis of Solid Tumors: An Overview. 2009 , 5, 51-65	
168	Immunosuppressive Agents for the Prevention of Transplantation Rejection. 2010 , 983-1063	
167	Rapamycin and the transcription factor C/EBPbeta as a switch in osteoclast differentiation: implications for lytic bone diseases. 2010 , 88, 227-33	32
166	p53 and ARF: unexpected players in autophagy. 2010 , 20, 363-9	84
165	De novo therapy with everolimus, low-dose ciclosporine A, basiliximab and steroid elimination in pediatric kidney transplantation. 2010 , 10, 2349-54	53
164	A collection of caged compounds for probing roles of local translation in neurobiology. 2010 , 18, 7746-52	18
163	Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. 2010 , 20, 4308-12	68
162	Persistent effects of everolimus on strength of experimental wounds in intestine and fascia. 2010 , 18, 98-104	21
161	Potential use of rapamycin in HIV infection. 2010 , 70, 784-93	56
160	Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS). 2010 , 148, 205-16	92
159	Signaling pathways in the epithelial origins of pulmonary fibrosis. 2010 , 9, 2769-76	56
158	Role for mammalian target of rapamycin complex 1 signaling in neuroadaptations underlying alcohol-related disorders. 2010 , 107, 20093-8	114
157	Recent advances in the discovery of small molecule mTOR inhibitors. 2010 , 2, 1577-89	13
156	Mechanisms of life span extension by rapamycin in the fruit fly <i>Drosophila melanogaster</i> . 2010 , 11, 35-46	709
155	Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?. 2011 , 13, 49-69	25
154	Crohn's disease: NOD2, autophagy and ER stress converge. 2011 , 60, 1580-8	151
153	FKBP51 regulation of AKT/protein kinase B phosphorylation. 2011 , 11, 360-4	36

152	A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. 2011 , 47, 1484-9	22
151	Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. 2011 , 192, 615-29	362
150	Recent clinical trials of mTOR-targeted cancer therapies. 2011 , 6, 24-35	63
149	Rapamycin Regulates Bleomycin-Induced Lung Damage in SP-C-Deficient Mice. 2011 , 2011, 653524	22
148	Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data. 2011 , 92, 658-62	41
147	Natural products as a source of protein kinase activators and inhibitors. 2011 , 11, 1333-9	4
146	Inhibition of induced autophagy increases apoptosis of Nara-H cells. 2011 , 39, 1545-52	4
145	Everolimus-induced loss of wound strength can be prevented by a short postoperative delay in its administration. 2011 , 19, 680-6	7
144	mTOR as a multifunctional therapeutic target in HIV infection. 2011 , 16, 715-21	84
143	Targeting the autophagy pathway using ectopic expression of Beclin 1 in combination with rapamycin in drug-resistant v-Ha-ras-transformed NIH 3T3 cells. 2011 , 31, 231-8	33
142	Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors. 2011 , 4, 3	20
141	Mammalian target of rapamycin and head and neck squamous cell carcinoma. 2011 , 3, 22	24
140	Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats. 2011 , 26, 92-100	56
139	Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. 2011 , 17, 1956-63	35
138	Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis. 2011 , 11, 1181-92	60
137	MEK-ERK pathway modulation ameliorates pulmonary fibrosis associated with epidermal growth factor receptor activation. 2012 , 46, 380-8	78
136	[PI3K-AKT-mTOR pathway and cancer]. 2012 , 99, 173-80	22
135	An evaluation of sirolimus in renal transplantation. 2012 , 8, 1337-56	23

134	New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome. 2012 , 24, 1-8	83
133	Everolimus in pediatric transplantation. 2012 , 17, 515-9	8
132	mTOR Inhibitors in Tuberous Sclerosis Complex. 2012 , 10, 404-415	94
131	Preparation and in vivo evaluation of liposomal everolimus for lung carcinoma and thyroid carcinoma. 2012 , 35, 975-9	19
130	Pro-autophagic polyphenols reduce the acetylation of cytoplasmic proteins. 2012 , 11, 3851-60	79
129	Formation of tRNA granules in the nucleus of heat-induced human cells. 2012 , 418, 149-55	25
128	Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. 2012 , 142, e1S-e111S	37
127	A single suprathreshold dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer. 2012 , 70, 567-74	1
126	Potential role of enzastaurin in the treatment of patients with relapsed or refractory advanced cutaneous T-cell lymphomas: a review. 2012 , 1	
125	Role of autophagy in immunity and autoimmunity, with a special focus on systemic lupus erythematosus. 2012 , 26, 1400-12	115
124	Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling. 2012 , 287, 17530-17545	110
123	The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus. 2012 , 69, 1247-53	4
122	The minimal impact of food on the pharmacokinetics of ridaforolimus. 2012 , 70, 177-82	4
121	The role of external beam radiation and targeted therapy in thyroid cancer. 2012 , 22, 254-62	26
120	Comparative study of rapamycin and temsirolimus demonstrates superimposable anti-tumour potency on prostate cancer cells. 2013 , 112, 63-9	14
119	Is mTOR inhibition a systemic treatment for tuberous sclerosis?. 2013 , 39, 57	41
118	mTOR kinase, a key player in the regulation of glial functions: relevance for the therapy of multiple sclerosis. 2013 , 61, 301-11	65
117	Carbamazepine suppresses calpain-mediated autophagy impairment after ischemia/reperfusion in mouse livers. 2013 , 273, 600-10	33

116	Application and interpretation of current autophagy inhibitors and activators. 2013 , 34, 625-35	223
115	Therapeutic agents triggering nonapoptotic cancer cell death. 2013 , 56, 4823-39	59
114	Effects of aging, antiaging calorie restriction and in vivo stimulation of autophagy on the urinary excretion of 8OHdG in male Sprague-Dawley rats. 2013 , 35, 261-70	14
113	Novel frontiers in epilepsy treatments: preventing epileptogenesis by targeting inflammation. 2013 , 13, 615-25	27
112	Rapamycin inhibits the mTOR/p70S6K pathway and attenuates cardiac fibrosis in adriamycin-induced dilated cardiomyopathy. 2013 , 61, 223-8	28
111	Degradation of initiator tRNAMet by Xrn1/2 via its accumulation in the nucleus of heat-treated HeLa cells. 2013 , 41, 4671-85	29
110	mTOR Inhibition: From Aging to Autism and Beyond. 2013 , 2013, 849186	40
109	Rapamycin inhibits transforming growth factor β -induced fibrogenesis in primary human lung fibroblasts. 2013 , 54, 437-44	25
108	Genome-wide association study for biomarker identification of Rapamycin and Everolimus using a lymphoblastoid cell line system. 2013 , 4, 166	12
107	Immunosuppression in Transplantation. 2014 , 741-751	
106	The mammalian target of rapamycin pathway in the basolateral amygdala is critical for nicotine-induced behavioural sensitization. 2014 , 17, 1881-94	12
105	Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: model prediction and clinical confirmation. 2014 , 54, 1256-62	2
104	mTOR complex 1: a key player in neuroadaptations induced by drugs of abuse. 2014 , 130, 172-84	81
103	Clinical significance of mTOR, ZEB1, ROCK1 expression in lung tissues of pulmonary fibrosis patients. 2014 , 14, 168	29
102	Impaired clearance of apoptotic cells in chronic inflammatory diseases: therapeutic implications. 2014 , 5, 354	57
101	mTOR inhibitors in pediatric kidney transplantation. 2014 , 29, 1119-29	32
100	New horizons for old drugs and drug leads. 2014 , 77, 703-23	176
99	mTOR regulates the nucleoplasmic diffusion of Xrn2 under conditions of heat stress. 2014 , 588, 3454-60	8

98	Rapamycin promotes podocyte autophagy and ameliorates renal injury in diabetic mice. 2014 , 394, 145-54	55
97	Phenotypic screening in cancer drug discovery - past, present and future. 2014 , 13, 588-602	307
96	Modern Cancer Drug Discovery. 2014 , 3-53	5
95	Rapamycin prevents drug seeking via disrupting reconsolidation of reward memory in rats. 2014 , 17, 127-36	42
94	Successful treatment of Kaposiform hemangioendothelioma with everolimus. 2015 , 62, 536-8	30
93	mTOR kinase: a possible pharmacological target in the management of chronic pain. 2015 , 2015, 394257	45
92	Autophagy and liver ischemia-reperfusion injury. 2015 , 2015, 417590	79
91	P70S6 kinase phosphorylation: a new site to assess pharmacodynamics of sirolimus. 2015 , 128, 664-9	2
90	Autophagy plays an important role in triptolide-induced apoptosis in cardiomyocytes. 2015 , 236, 168-83	33
89	MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma. 2015 , 14, 395-406	70
88	Effects of the mTOR inhibitor everolimus and the PI3K/mTOR inhibitor NVP-BEZ235 in murine acute lung injury models. 2015 , 33, 45-50	8
87	Effects of rapamycin against paraquat-induced pulmonary fibrosis in mice. 2015 , 16, 52-61	19
86	The renoprotective role of autophagy activation in proximal tubular epithelial cells in diabetic nephropathy. 2015 , 29, 976-83	25
85	Key autophagic targets and relevant small-molecule compounds in cancer therapy. 2015 , 48, 7-16	12
84	mTOR and Neuroinflammation. 2016 , 317-329	4
83	mTOR in Multiple Sclerosis: The Emerging Role in the Regulation of Glial Biology. 2016 , 331-343	2
82	mTOR and Drugs of Abuse. 2016 , 215-226	
81	Efficacy and Safety of Mammalian Target of Rapamycin Inhibitors in Vascular Anomalies: A Systematic Review. 2016 , 96, 448-52	51

80	mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm. 2016 , 138, 2312-21	58
79	How I manage Evans Syndrome and AIHA cases in children. 2016 , 172, 524-34	59
78	Targeting Cancer Cell Death with Small Molecule Agents for Potential Therapeutics. 2016 , 211-230	
77	Apoptosis Methods in Toxicology. 2016 ,	1
76	Unique and Redundant Functions of p70 Ribosomal S6 Kinase Isoforms Regulate Mesenchymal Cell Proliferation and Migration in Pulmonary Fibrosis. 2016 , 55, 792-803	7
75	Multiple eruptive angiofibromas in a 14-year-old girl. 2016 , 14, 746-748	
74	Effects of chemotherapy agents on Sphingosine-1-Phosphate receptors expression in MCF-7 mammary cancer cells. 2016 , 81, 218-224	11
73	Recent Advances in Adipose mTOR Signaling and Function: Therapeutic Prospects. 2016 , 37, 303-317	76
72	p70 ribosomal S6 kinase regulates subpleural fibrosis following transforming growth factor- β expression in the lung. 2016 , 310, L175-86	13
71	Autophagy upregulation promotes macrophages to escape mesoporous silica nanoparticle (MSN)-induced NF- κ B-dependent inflammation. 2016 , 65, 325-41	30
70	Suppression of lytic replication of Kaposi's sarcoma-associated herpesvirus by autophagy during initial infection in NIH 3T3 fibroblasts. 2016 , 161, 595-604	4
69	Sirtuins, a promising target in slowing down the ageing process. 2017 , 18, 447-476	220
68	Sirolimus therapy for children with problematic kaposiform haemangioendothelioma and tufted angioma. 2017 , 177, e344-e346	14
67	The role of the TOR pathway in mediating the link between nutrition and longevity. 2017 , 164, 127-138	48
66	Autophagy protects auditory hair cells against neomycin-induced damage. 2017 , 13, 1884-1904	141
65	hnRNPM guides an alternative splicing program in response to inhibition of the PI3K/AKT/mTOR pathway in Ewing sarcoma cells. 2017 , 45, 12270-12284	33
64	A progressive reduction in autophagic capacity contributes to induction of replicative senescence in Hs68 cells. 2017 , 92, 18-25	5
63	Kinetics studies of the degradation of sirolimus in solid state and in liquid medium. 2017 , 130, 1653-1661	6

62	Sirolimus in the Treatment of Vascular Anomalies. 2017 , 27, 86-90	81
61	Pulmonary lymphatic vessel morphology: a review. 2018 , 218, 110-117	18
60	Multidisciplinary Approach to the Management of Lymphatic Malformations of the Head and Neck. 2018 , 51, 159-172	15
59	Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients. 2018 , 81, 347-354	3
58	Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells. 2018 , 18, 63	32
57	Nanomedicine approaches for sirolimus delivery: a review of pharmaceutical properties and preclinical studies. 2018 , 46, 1-14	57
56	Rapamycin Treatment Ameliorates Age-Related Accumulation of Toxic Metabolic Intermediates in Brains of the Ts65Dn Mouse Model of Down Syndrome and Aging. 2018 , 10, 263	9
55	The role of endothelial colony forming cells in kidney cancer's pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review. 2018 , 132, 89-99	22
54	Efficacy and absorption of topical sirolimus for the treatment of vascular anomalies in children: A case series. 2018 , 35, 472-477	19
53	Inhibiting autophagy reduces retinal degeneration caused by protein misfolding. 2018 , 14, 1226-1238	42
52	Rapamycin Protects Against Peritendinous Fibrosis Through Activation of Autophagy. 2018 , 9, 402	21
51	Oral and Topical Sirolimus for Vascular Anomalies: A Multicentre Study and Review. 2019 , 99, 990-996	22
50	Genetic Pathways of Aging and Their Relevance in the Dog as a Natural Model of Human Aging. 2019 , 10, 948	18
49	Salivary Gland Hypofunction and Xerostomia in Head and Neck Radiation Patients. 2019 , 2019,	43
48	A Case of Suspected Adverse Reactions to Sirolimus in the Treatment of Generalized Lymphatic Anomaly. 2019 , 2019, 3101357	1
47	Old treatments for new genetic conditions: Sirolimus therapy in a child affected by mosaic overgrowth with fibroadipose hyperplasia. 2019 , 96, 102-103	4
46	Oral Sirolimus: An Option in the Management of Neonates with Life-Threatening Upper Airway Lymphatic Malformations. 2019 , 17, 504-511	14
45	The Role of Curcumin in the Modulation of Ageing. 2019 , 20,	55

44	Oligo(Lactic Acid)-Rapamycin Prodrug-Loaded Poly(Ethylene Glycol)-block-Poly(Lactic Acid) Micelles for Injection. 2019 , 36, 70	7
43	Trehalose restores functional autophagy suppressed by high glucose. 2019 , 85, 51-58	12
42	Assessing the efficacy of mammalian target of rapamycin inhibitors by phosphorylation of p70S6K in CD4-positive cells of liver transplant patients. 2019 , 98, e17457	1
41	Common (Cystic) Lymphatic Malformations: Current Knowledge and Management. 2019 , 22, 100631	14
40	Rapamycin in ischemic stroke: Old drug, new tricks?. 2019 , 39, 20-35	19
39	Minocycline Induces Autophagy and Inhibits Cell Proliferation in LPS-Stimulated THP-1 Cells. 2020 , 2020, 5459209	7
38	Suppression of Drug-Resistant Non-Small-Cell Lung Cancer with Inhibitors Targeting Minichromosomal Maintenance Protein. 2020 , 63, 3172-3187	6
37	Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 487-493	6.1 13
36	Case Report: A Novel Pathogenic Missense Mutation in : A Multi-Generational Case Series of Autoimmune Lymphoproliferative Syndrome. 2021 , 9, 624116	2
35	Is targeting autophagy mechanism in cancer a good approach? The possible double-edge sword effect. 2021 , 11, 56	14
34	Molecular mechanisms of action of Trehalose in cancer: A comprehensive review. 2021 , 269, 118968	3
33	Single Center Experience of Sirolimus Therapy in Head and Neck Low-flow Vascular Malformations. 2021 , 55, 482-490	2
32	Tuberous Sclerosis Complex. 2021 , 37, 100875	4
31	Effects of sirolimus in the treatment of unresectable infantile hemangioma and vascular malformations in children: A single-center experience. 2021 , 9, 1488-1494	0
30	Baseline effector cells predict response and NKT cells predict pulmonary toxicity in advanced breast cancer patients treated with everolimus and exemestane. 2021 , 93, 107404	0
29	FOXG1 promotes aging inner ear hair cell survival through activation of the autophagy pathway. 2021 , 1-22	32
28	Interventional Strategies to Delay Aging-Related Dysfunctions of the Musculoskeletal System.	
27	Efficacy of Sirolimus in Patients Requiring Tracheostomy for Life-Threatening Lymphatic Malformation of the Head and Neck: A Report From the European Reference Network. 2021 , 9, 697960	1

26	Mechanisms of resistance to mTOR inhibitors. 2020 , 147, 102886	12
25	CCR3 and choroidal neovascularization. 2011 , 6, e17106	29
24	Nanoparticles Effectively Target Rapamycin Delivery to Sites of Experimental Aortic Aneurysm in Rats. 2016 , 11, e0157813	28
23	The mTOR kinase inhibitor rapamycin enhances the expression and release of pro-inflammatory cytokine interleukin 6 modulating the activation of human microglial cells. 2019 , 18, 779-798	4
22	Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma. 2017 , 8, 22203-22217	63
21	mTOR Inhibitors in Tuberous Sclerosis Complex. 2012 , 10, 404-15	50
20	Comparison of sirolimus and colchicine treatment on the development of peritoneal fibrosis in rats having peritoneal dialysis. 2015 , 32, 101-6	3
19	Current development of the second generation of mTOR inhibitors as anticancer agents. 2012 , 31, 8-18	67
18	Autophagy downregulation contributes to insulin resistance mediated injury in insulin receptor knockout podocytes in vitro. 2016 , 4, e1888	17
17	A Single-Arm Open-Label Clinical Trial on the Efficacy and Safety of Sirolimus for Epileptic Seizures Associated with Focal Cortical Dysplasia Type II: A Study Protocol. 2021 , 66, 115-120	1
16	Pediatric Vascular Anomalies: Opportunities in Primary Care. 2021 , 453-486	0
15	An Overview of the Design, Development and Applications of Biodegradable Stents. 2020 , 10, 2-13	
14	Blockade of the mTOR signaling pathway with rapamycin ameliorates aristolochic acid nephropathy. 2020 , 19, 2887-2894	1
13	Effectiveness of inhibitor rapamycin, saracatinib, linsitinib and JNJ-38877605 against human prostate cancer cells. 2015 , 8, 6563-7	2
12	Chaiqi decoction ameliorates vascular endothelial injury in metabolic syndrome by upregulating autophagy. 2020 , 12, 4902-4922	
11	Effective low dose sirolimus regimen for kaposiform hemangioendothelioma with Kasabach-Merrit Phenomenon in young infants.. 2021 ,	1
10	Injectable hydrogel microspheres with self-renewable hydration layers alleviate osteoarthritis.. 2022 , 8, eabl6449	6
9	Efficacy of mTOR inhibitors (sirolimus) in isolated limb overgrowth: a systematic review.. 2022 , 17531934211073866	

8 DataSheet_1.pdf. **2019**,

7 Data_Sheet_1.DOCX. **2018**,

6 Image_1.jpg. **2018**,

5 Image_2.jpg. **2018**,

4 Sirolimus relieves seizures and neuropsychiatric symptoms via changes of microglial polarity in tuberous sclerosis complex model mice. **2022**, 218, 109203

3 Polycystic Liver Disease: Pathophysiology, Diagnosis and Treatment. Volume 14, 135-161

2 Neuropeptide signaling and addiction: what have learned from Drosophila?. **2022**, 100037

1 Safety of Sirolimus in Patients with Tuberous Sclerosis Complex under Two Years of Age: A Bicenter Retrospective Study. **2023**, 12, 365